INTRODUCTION
Immune checkpoint blockade has emerged as a major tool for harnessing the immune system to control malignancy. 1 Three agents have already been approved by the US Food and Drug Administration in several adult malignancies, [2] [3] [4] and several more are in clinical trials. 5, 6 Phase 3 clinical trials have demonstrated that agents that disrupt the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have significant efficacy, including the ability to induce complete responses and prolong survival in previously untreatable cancers.
7-9 PD-1 blocking agents have exhibited activity across a wide range of histologies, from hematologic malignancies 10, 11 to solid tumors. 7, 12, 13 By blocking the interaction of the T-cell coreceptor PD-1 to its ligands, PD-L1 and PD-L2, these agents disinhibit T cells and promote an antitumor immune response.
Pediatric oncology has witnessed great improvements in survival largely through the administration and optimization of combination chemotherapy. Impressive reductions in cancer deaths and treatment-related mortality have been reported with leukemias, lymphomas, and localized sarcomas. 14 However, limited progress has occurred for specific clinical groups, including metastatic solid tumors and brain tumors, related in part to de novo and acquired resistance to chemotherapy. [15] [16] [17] Immunotherapy presents a promising modality in pediatric oncology that may offer a new therapeutic option for patients with chemotherapy-refractory disease. [18] [19] [20] Ch14.18, a chimeric anti-GD2 monoclonal antibody, increases survival in pediatric patients with metastatic neuroblastoma, 21 and chimeric antigen receptor-modified T cells have shown promise in early phase clinical trials among children with relapsed leukemia. 22, 23 However, to date, there have been limited preclinical or clinical data focused on checkpoint blockade for pediatric cancers. A phase 1 pediatric trial of ipilimumab was completed but did not produce objective responses. 24 Clinical studies of PD-1 blockade have not yet been completed in pediatric patients, and little is known regarding PD-L1 expression in common childhood cancers. Some studies have implicated tumor expression of PD-L1 as a negative prognostic factor in cancer 7, 25, 26 and as a predictor of response after treatment with PD-1-blocking antibodies. 27, 28 In this study, we characterized PD-L1 expression in a wide variety of pediatric tumor samples. In addition, to further understand the immune microenvironment in pediatric cancer, we identified tumor associated immune cells (TAICs) (lymphocytes and macrophages) in these samples by immunohistochemistry (IHC).
MATERIALS AND METHODS

Tumor Samples
Archived samples representing a variety of pediatric tumor types were obtained from multiple sources. Whole slide sections of osteosarcoma (N 5 20) as well as several tumor microarrays (TMAs) were obtained from the Children's Hospital of Philadelphia. Each TMA was comprised of 0.6-mm cores in duplicate, triplicate, or greater. Whole slide sections (N 5 71) of Ewing sarcoma, neuroblastoma, rhabdomyosarcoma, and Burkitt lymphoma were obtained from Gustave Roussy Comprehensive Cancer Center (Villejuif, France). Tumors were diagnostic samples with the exception of 5 recurrent ependymoma samples and 7 post-therapy neuroblastoma samples. Informed consent was obtained from all patients or their guardians for use of their samples for research, and local institutional review boards confirmed that this analysis did not constitute human subjects research.
Assessment of PD-L1 and TAICs by Immunohistochemistry
An automated and validated PD-L1 IHC assay codeveloped by Bristol-Myers Squibb (New York, NY) and Dako (Carpinteria, Calif) with a rabbit antihuman PD-L1 antibody (clone 28-8) from Epitomics Inc (Burlingame, Calif) was used to assess PD-L1 expression in archived tumor samples. 29 Analyses were performed at Mosaic Laboratories (Lake Forest, Calif) by personnel trained in the use of the assay. Deparaffinization, rehydration, and target retrieval were performed in the target-retrieval solution on the Dako PT Link pretreatment module. PD-L1 staining was conducted on a Dako Autostainer Link 48 using the following general procedure, with a buffer rinse performed after each step: peroxidase-blocking, followed by PD-L1 antibody application, followed by antirabbit linker application, followed by visualization reagent application, followed by diaminobenzidine application, followed by diaminobenzidine enhancer application, followed by hematoxylin application.
Scoring for PD-L1 expression was performed manually by a pathologist trained in the assessment of the Dako PD-L1 IHC assay. Positive cellular staining was defined as complete circumferential or partial linear plasma membrane staining. Negative cellular staining was defined as no staining of the plasma membrane. Positive tumor samples were scored according to the percentage of tumor cells that had 1 1 or greater plasma membrane staining, with a minimum of 100 cells evaluated. Samples were considered uninterpretable if <100 cells were scored.
Identification of TAICs
All samples were assessed for the presence of lymphocytes and macrophages (eg, TAICs) by histology, and TAICs were visually assessed for the presence of PD-L1 expression. A sample was considered positive for TAICs if it contained any lymphocytes or macrophages by hematoxylin and eosin (H&E) staining. TAICs were defined as PD-L1-positive if there was complete circumferential or partial linear staining of the plasma membrane of any cells.
RESULTS
PD-L1 Expression
All 91 whole slide samples and at least 1 core from 360 individual tumors on the TMAs had sufficient tissue present to allow counts of >100 cells and thus were judged as adequate for analysis (N 5 451). The source of all samples (TMA or whole slides) as well as the details of their acquisition before therapy (N 5 439) or after therapy (N 5 12) are provided in Supporting Table 1 (see online supporting information). Tumor cells in 39 samples (9%) ( Table 1) stained positive for PD-L1 above a 1% threshold 30, 31 (range, 1%-50% of tumor cells; median, 2%). The highest proportion of positive samples was observed in Burkitt lymphoma, in which 8 of 10 samples (80%) were positive for PD-L1. PD-L1 staining also was observed frequently in glioblastoma multiforme (GBM) (5 of 14 samples; 36%) and neuroblastoma (17 of 118 samples; 14%). Other histotypes that demonstrated PD-L1 positivity included ganglioneuroblastoma (2 of 18 samples; 11%), Original Article ependymoma (2 of 42 samples; 5%), osteosarcoma (1 of 20 samples; 5%), rhabdomyosarcoma (1 of 53 samples; 2%), and synovial sarcoma (1 of 1 sample; 100%). Representative images are provided in Figure 1 . Details of all PD-L1-positie samples, including PD-L1 scoring, are available in Supporting Table 2 (see online supporting information). There was no statistically significant difference between PD-L1 staining scores derived from the TMAs or the whole slides. PD-L1 staining was not observed in Ewing sarcoma (N 5 25) or medulloblastoma (N 5 40).
TAICs
TAICs were identified using standard H&E microscopy in the majority of samples (333 of 451; 74%). Twenty percent (92 of 451) of all samples contained macrophages, and 72% (323 of 451 samples) contained lymphocytes. Of the TAIC-containing samples, the majority contained lymphocytes only (242 of 333 samples; 72%), whereas 24% (81 of 333 samples) contained lymphocytes and macrophages, and only 3% (11 of 333 samples) contained macrophages in the absence of lymphocytes. (14) 36 (5) 71 (10) 7 (1) 20 (2) Neuroblastoma (118) 14 (17) 83 (98) 32 (38) 24 (24) Ganglioneuroblastoma (18) 11 (2) 89 (16) 0 (0) 0 (0) Atypical teratoid/rhabdoid tumor (16) 6 (1) 94 (15) 0 (0) 13 (2) Ependymoma (42) 5 (2) 62 (26) 0 (0) 4 (1) Osteosarcoma (20) 5 (1) 100 (20) 70 (14) 45 (9) Rhabdomyosarcoma (53) 2 (1) 89 (47) 28 (15) 30 (14) Synovial sarcoma (1) 100 (1) 100 (1) 100 (1) 100 (1) Supratentorial PNET (5) 20 (1) 60 (3) 0 (0) 0 (0) Ewing sarcoma and peripheral PNET (25) 0 (0) 92 (23) 44 (11) 35 (8) Medulloblastoma (40) 0 (0) 63 (25) 3 (1) 0 (0) Astrocytoma, WHO Grades 1-2 (63) 0 (0) 38 (24) 0 (0) 0 (0) Anaplastic astrocytoma and anaplastic oligodendroglioma (7) 0 (0)
Wilms tumor (4) 0 (0) 100 (4) 25 (1) 25 (1) Ganglioneuroma (10) 0 (0) 70 (451) 9 (39) 72 ( The majority of PD-L1-positive samples were infiltrated by TAICs (34 of 39 samples; 87%). Lymphocytes were present in similar percentages of both PD-L1-positive (27 of 39 samples; 69%) and negative (296 of 412 samples; 72%) samples. However, PD-L1-positive samples were significantly more likely to contain macrophages (20 of 39 samples; 51%) than PD-L1-negative samples (72 of 412 samples; 17%; P < .001; Fisher exact test). This is represented in Figure 2a .
TAICs also stained positive for PD-L1 (71 of 333 samples; 21% of those with TAIC). When macrophages were present in samples, they were mostly positive for PD-L1 (60 of 92 samples; 65%), whereas lymphocytes rarely stained positive for PD-L1 (22 of 323 samples; 7%; P < .001; Fisher exact test). This is represented in Figure  2b . Taken together, PD-L1 was expressed on tumor cells and/or immune cells in 20% of samples (89 of 451 of all samples).
All osteosarcoma samples (20 of 20; 100%) were infiltrated by lymphocytes. Similarly, the majority of Ewing sarcoma (92%), rhabdomyosarcoma (89%), neuroblastoma (83%), glioblastoma (71%), medulloblastoma (63%), and ependymoma (62%) samples contained lymphocytes. In addition, a high percentage of Burkitt lymphoma (100%), osteosarcoma (70%), Ewing sarcoma (44%), and rhabdomyosarcoma (72%) samples contained macrophages.
Survival Data for Neuroblastoma Samples
Survival data were available for 94% (104 of 111 tumors) of the pretreatment neuroblastoma samples but not for other histologies. The other 7 neuroblastoma samples were obtained after systemic treatment and were not included in the analysis. Kaplan-Meier survival curves differed significantly by PD-L1 expression on the tumor cells and/or TAICs, with poorer survival for PD-L1-positive patients (P 5 .004; log-rank test) (Fig. 3a) . A trend toward statistical significance was maintained when evaluating samples that expressed PD-L1 only on tumor cells (P 5 .06; log-rank test). No significant differences in survival were observed between samples that did and did not contain TAICs (data not shown). International Neuroblastoma Staging System staging and risk group classification were available for 98 of the 104 samples in the survival analysis. There was a significant decrease in survival probability for patients with stage IV disease (N 5 29) whose tumors expressed PD-L1 (P 5 .04; logrank test) (Fig. 3b ) and for high-risk patients (N 5 30) whose tumors expressed PD-L1 (P 5 .05; log-rank test) (Fig. 3c) . No survival differences by PD-L1 expression were observed for patients with stage I, II, or III disease or for those with intermediate-risk and low-risk disease, although the analysis was underpowered because there were only 2 deaths among these patients. International Neuroblastoma Staging System stage, risk group classification, and PD-L1 expression in samples from the data set are provided in Figure 3d ,e. No statistically significant differences were observed in the frequency of PD-L1 expression between any stages or any risk groups. There was no relation in chi-square analysis between V-Myc avian myelocytomatosis viral oncogene neuroblastomaderived homolog (MYCN) amplification (N 5 10 positive, N 5 74 negative) and PD-L1 expression.
DISCUSSION
Here, we report the first broad screen of primary pediatric tumor samples for expression of PD-L1 and the presence of TAICs. Although multiple studies have investigated at PD-L1 expression in adult tumors, [32] [33] [34] [35] only limited, small studies of PD-L1 expression have been conducted in pediatric cancer. [36] [37] [38] [39] We identified PD-L1 in the majority of Burkitt lymphoma samples (80%) and in lower but significant fractions of GBM (36%), neuroblastoma (14%), and ganglioneuroblastoma (11%) samples. PD-L1 expression in Burkitt lymphoma has not previously been reported, but this observation parallels reports of PD-L1 expression in other B-cell lymphomas. [40] [41] [42] High rates of PD-L1 expression have previously been reported in adult GBM, and the level of expression has been correlated with the grade of the tumor. 43, 44 The results presented here raise the prospect of a similar immunobiology in pediatric glioblastoma, despite differing oncologic profiles. [45] [46] [47] PD-L1 expression in a large number of neuroblastoma biopsies has not previously been reported. One previous study reported no PD-L1 expression in a limited data set of 18 patients. 38 In our data set of more than 100 samples, patients whose samples stained positive for PD-L1 had inferior survival compared with those whose samples were PD-L1-negative. To our knowledge, this is the first report of a survival detriment for PD-L1 expression in neuroblastoma and complements what has been observed with other cancers. 7, 25, 26, 34, 37 Outside of these select histologies, the expression of PD-L1 in our series of pediatric tumors was low, and few sarcoma samples expressed PD-L1. This is not entirely surprising given recent reports of limited PD-L1 expression in adult sarcomas, 48 and it may relate to the relatively low mutational burden of pediatric cancers and translocation-associated sarcomas. [49] [50] [51] [52] [53] We report a rate of PD-L1 positivity in osteosarcoma (5%) that is lower than that in some previous studies, which included both adult and pediatric samples, 31, 54 but it compares favorably with data obtained from TMAs in other studies. 31 When considering expression on TAICs, mainly macrophages, in addition to tumor cells, 20% of all samples were PD-L1-positive. This rate was even higher in certain subgroups, such as osteosarcoma (45%), rhabdomyosarcoma (30%), and Ewing sarcoma (32%). A study by Chowdhury et al found higher rates of PD-L1 expression in a series of 115 pediatric tumors, 55 but their study relied on an antibody that was not validated for the detection of PD-L1. 56 Despite the modest levels of PD-L1 expression observed in this study, lymphocytic infiltration was observed in a large majority of our samples. Although current concepts hold that PD-L1 expression may serve as a marker of lymphocyte activation and production of interferon-c within the tumor microenvironment, 57 we did not observe a correlation between lymphocyte infiltration and PD-L1 expression in this data set. Rather, PD-L1 expression correlated with macrophage infiltration, suggesting the possibility that mechanisms of PD-L1 expression in pediatric tumors may be associated with a unique biology. Previous studies have reported a predominance of macrophages in pediatric tumors 58, 59 ; whereas, in our samples, a minority of tumors demonstrated macrophage infiltration, and these macrophages often expressed PD-L1. In mouse models, pediatric tumors induced myeloid-derived suppressor cells, which can aid in immune escape, 60 and pediatric sarcomas induced the expansion of such cells in patients. 61 We hypothesize that these tumors can signal myeloid cells, such as macrophages, to migrate to the tumor and aid in immune escape by expressing PD-L1. Despite the high rates of lymphocytic infiltration observed in a subset of pediatric tumors, attempts at growing tumor-infiltrating lymphocytes from pediatric tumors have largely been unsuccessful. 62 This is the first large study to systemically interrogate PD-L1 expression and TAICs in childhood cancer, but several limitations of the study should be noted. First, although we screened a large series of primary tumor samples, the numbers of samples available for some histologic subsets were small, and clinical correlation was not available for most disease types, precluding an assessment of the potential prognostic impact of PD-L1 for diseases other than neuroblastoma. Although the vast majority of samples were diagnostic and likely came from primary tumor sites, because they are the usual source of tissue in pediatric cancer, we could not confirm the exact source (primary vs metastatic) for individual cases. Second, given the low frequency of tumor cells that express PD-L1 and the heterogeneous distribution observed in many cancers, 63 the use of TMAs likely underestimates the true rate of PD-L1 expression given the limited sample size for each tumor studied. We used a cutoff of 1% of cells expressing PD-L1 as positive given that we stained TMAs, which capture just a small section of the tumor that often does not include the margin where PD-L1-positive cells are more likely to be located. 30, 31, 54 Third, emerging evidence suggests that pediatric cancer genomes evolve extensively after exposure to chemoradiotherapy and attain significantly larger mutational burdens. 53 Given that PD-L1 expression may be correlated with mutational burden, 64, 65 analysis of samples obtained at the time of diagnosis may underestimate PD-L1 expression at the time of recurrent disease. 54 Together, our data demonstrate that significant subsets of pediatric tumors express PD-L1, either on the tumor itself or in the microenvironment. The novel finding of frequent PD-L1 expression in Burkitt lymphoma suggests that further studies are warranted to determine whether the PD-1/PD-L1 axis is a good therapeutic target as has been Original Article established with other types of lymphoma. 10 We also observed that a significant fraction of GBM and neuroblastoma samples express PD-L1, raising the prospect of the utility of anti-PD1 therapies in these difficult to treat diseases. Finally, this is the first work to demonstrate differential outcomes based on PD-L1 expression in neuroblastoma. Further studies are needed to better delineate the immune cells present within the tumor microenvironment of pediatric cancers and to assess the role of anti-PD-1 therapies in the treatment of pediatric malignancies. 
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